Table 1. Clinical characteristics of 89 HIV-positive patients coinfected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
| Patients with LAM-R HBV (n = 33) | Patients with LAM-S HBV (n = 56) | P value | |
|---|---|---|---|
| Age, years | 42 ± 8 | 36 ± 8 | 0.001 |
| Male sex | 33 (100) | 55 (98.2) | 0.999 |
| Years since HIV diagnosis | 12.8 ± 4.7 | 5.2 ± 2.9 | <0.001 |
| HBV genotype | |||
| B | 28/33 (84.8) | 37/43 (86.0) | 0.999 |
| C | 5/33 (15.2) | 6/43 (14.0) | |
| No data | 0 | 13 | |
| Previous LAM use, years | 6.5 ± 3.9 | NA | |
| Positive HBeAg at baseline | 16/33 (48.5) | 18/55 (32.7) | 0.142 |
| HBsAg level at baseline, log10 IU/mL | 5.3 ± 2.1 (n = 33) | 3.5 ± 1.0 (n = 38) | <0.001 |
| Plasma HBV DNA level at enrollment, log10 copies/mL | 6.1 ± 2.2 | 6.0 ± 2.2 | 0.895 |
| 3–5 log10 copies/mL | 14 (42.4) | 23 (41.1) | |
| >5 log10 copies/mL | 19 (57.6) | 33 (58.9) | |
| Hepatitis flares within the preceding one year of enrollment | 7 (21.2) | NA | |
| ALT at baseline, IU/L | 56 ± 55 | 52 ± 48 | 0.383 |
| APRI score at baseline | 0.5 ± 0.4 | 0.9 ± 1.4 | 0.099 |
| Cirrhosis or parenchymal liver disease at baseline | 10/31 (32.2) | 10/39 (25.6) | 0.543 |
| Chronic HCV infection at baseline | 0 (0) | 2 (3.6) | |
| CD4 cell count at baseline, cells/μl | 552 ± 382 | 249 ± 220 | <0.001 |
| Plasma HIV RNA load at baseline, log10 copies/mL, | 1.7 ± 0.6 | 4.9 ± 0.6 | <0.001 |
| Plasma HIV RNA load <200 copies/mL at baseline | 31 (93.9) | 0 (0) | |
| NRTI backbone before tenofovir and lamivudine | |||
| Zidovudine/lamivudine | 10 (30.3) | NA | |
| Abacavir/lamivudine | 22 (66.7) | NA | |
| Didanosine and lamivudine | 1 (3) | NA | |
| NNRTI-based cART | 15 (45.5) | 39 (69.6) | 0.024 |
| PI-based cART | 18 (54.5) | 14 (25) | 0.005 |
| II-based cART | 0 (0) | 3 (5.4) | |
| Follow-up duration, weeks, | 202 ± 58 | 147 ± 54 | <0.001 |
Results are n (%), or mean ± standard deviation.
Abbreviations: ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; cART, combination antiretroviral therapy; HBV, hepatitis B virus; HBeAg, HBV envelope antigen; HBsAg, HBV surface antigen; HCV, hepatitis C virus; II, integrase inhibitor; LAM, lamivudine; LAM-R, LAM-resistant; LAM-S, LAM-susceptible; NA, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleos(t)ide reverse transcriptase inhibitors; PI, protease inhibitor.